title: [Ovulation induction in high risk IVF patients: GnRH-agonist, diminished dose of urinary or recombinant chorion gonadotropin].
abstract: In high risk IVF patients the ovulation triggering was done with agonist (0.2 mg), 1.gr., Pregnyl 5000 IE, 2. and 4.gr., Ovitrelle 0.250 mg, 3.gr., and Pregnyl 10000 IE in the fifth--non-risk group. The protocol of the first and fourth group included antagonist, the second and third group was with short and the fifth group with long agonist protocol. There was no grave OHSS in the first group, one case in each second, third and fourth group and 4 cases in the fifth group, as a whole 7 patients (3.3%). In all of them an abdominal drainage lasting 4 to 30 days was performed and all pregnancies were preserved. The average success rate was 50%, 71.4% in the fourth and 43.1% in the fifth group. A protocol with antagonist and ovulation triggering with agonist or reduced dose ChG in order to diminish OHSS in high risk IVF patients is recommended.
authors.forename: K
authors.initials: K
authors.lastname: Aleksandrov
authors.forename: G
authors.initials: G
authors.lastname: Kozovski
authors.forename: E
authors.initials: E
authors.lastname: Kovachev
authors.forename: M
authors.initials: M
authors.lastname: Angelova
authors.forename: V
authors.initials: V
authors.lastname: Markova
authors.forename: I
authors.initials: I
authors.lastname: Kozovski
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use / Q000652:urine; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D015292:Glycoprotein Hormones, alpha Subunit / Q000008:administration & dosage / Q000627:therapeutic use / Q000652:urine; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists* / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010062:Ovulation Induction / Q000379:methods*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use / Q000652:urine; D016896:Treatment Outcome
chemical_list: D006063:Chorionic Gonadotropin; D015292:Glycoprotein Hormones, alpha Subunit; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix